When evaluating SLU-PP-332 versus SR9009 as ERR agonists, researchers discover distinct differences in their mechanisms and applications. SLU-PP-332 demonstrates superior selectivity for estrogen-related receptor alpha (ERRα), while SR9009 primarily targets REV-ERB nuclear receptors. Both compounds serve critical roles in metabolic research and pharmaceutical development, yet their structural variations create unique opportunities for specific industrial applications. Understanding these differences helps manufacturers select the optimal compound for their particular research objectives and production requirements.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
250mcg/500mcg/1mg/5mg/10mg/20mg
(4)Injection
5mg/vial
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-1-145
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide CAS 303760-60-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide SLU-PP-332, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/slu-pp-332-peptide.html
Understanding ERR Agonist Mechanisms
Estrogen-related receptor agonists speak to an interesting course of chemical compounds that connect with atomic receptors to control the cellular digestive system. These particles bind to particular receptor locales, activating downstream signaling cascades that impact vitality homeostasis and mitochondrial function.
The atomic structure of SLU-PP-332 empowers it to illustrate remarkable official liking for ERRα receptors, with IC50 values extending from 1.2 to 2.8 μM. This selectivity makes it especially important to focus on investigate applications where exact receptor enactment is essential.
Three core mechanisms distinguish these agonists:
Receptor binding specificity: Different selectivity profiles for various receptor subtypes
Metabolic pathway activation: Unique downstream effects on cellular processes
Pharmacokinetic properties: Varying absorption, distribution, and elimination rates
The binding kinetics reveal important differences that impact industrial applications. Research data indicates that SLU-PP-332 maintains stable receptor occupancy for extended periods, while SR9009 exhibits more rapid dissociation rates.
If you need sustained receptor activation for extended research protocols, then SLU-PP-332 presents more suitable characteristics for your applications.
Chemical Structure Analysis
Examining the atomic engineering of these compounds uncovers why their natural exercises vary significantly. The auxiliary system of each particle decides its receptor authoritative properties and consequent pharmacological impacts, with key fluctuations in highlights like aromatic ring systems, hydrogen holding capacity, and lipophilicity profiles straightforwardly affecting their function and application.
Molecular Structure and Receptor Selectivity
The unmistakable organic action is established in each compound's particular basic system. SLU-PP-332, for occurrence, highlights a complex heterocyclic structure with useful groups that upgrade its selectivity for ERRα receptors. Its atomic weight of 456.5 g/mol and special stereochemistry make a particular official profile. Key auxiliary contrasts, such as varieties in fragrant ring substitution designs, hydrogen holding donor/acceptor courses of action, and lipophilicity values, in a general sense decide receptor acknowledgment, official partiality, and cellular penetrability, clarifying their unique pharmacological effects.
Stability and Analytical Characterization
Analytical information and soundness profiles are significant for commonsense application. High-resolution mass spectrometry affirms the basic astuteness of these compounds beneath standard capacity conditions. Eminently, temperature soundness considers illustrate that SLU-PP-332 keeps up its atomic structure at temperatures up to 40°C for periods surpassing six months, a key factor for capacity and dealing with conventions. This experimental information gives fundamental confirmation of the compound's versatility and underpins solid utilization in inquire about and advancement settings.
Synthetic Accessibility and Manufacturing
The achievability of generation is a major thought in compound choice. The engineered openness of these compounds changes impressively; fabricating courses for SLU-PP-332 regularly include multi-step natural union methods that require specialized gear and specialized skill. This complexity contrasts with more easily manufactured pathways. Hence, if unsurprising, versatile generation strategies are a need for venture arranging, a cautious assessment of the fabricating complexity and asset necessities for each target atom gets to be an fundamental step in the advancement process.
Comparative Performance Data
Performance metrics provide crucial insights for researchers and manufacturers evaluating these ERR agonists. Laboratory testing reveals significant differences in potency, selectivity, and stability profiles between the two compounds.
Binding affinity studies conducted using radioligand displacement assays show distinct patterns:
Stability testing under accelerated conditions reveals that SLU-PP-332 demonstrates remarkable chemical stability. After 12 months at controlled temperature and humidity, analytical purity remains above 98%, making it suitable for long-term research projects.
The solubility profiles also differ markedly. SLU-PP-332 shows enhanced solubility in polar organic solvents, while maintaining adequate stability in aqueous solutions at physiological pH levels.
Quality control analysis using HPLC-MS methods confirms that both compounds can achieve pharmaceutical-grade purity when manufactured under appropriate conditions. The analytical methods demonstrate reproducible results with relative standard deviations below 2%.
If you need compounds with superior chemical stability and extended shelf life, then SLU-PP-332 offers advantages for inventory management and quality assurance programs.
Industrial Applications and Use Cases
Applications in Pharmaceutical and Biotech Research
The pharmaceutical industry progressively recognizes the potential of Blunder agonists in sedate improvement programs. These compounds serve as important tools for exploring metabolic disorders and creating novel restorative approaches. Fabricating applications particularly span different mechanical divisions, including pharmaceutical research for lead compound optimization and component considers, biotechnology improvement for cellular digestion system investigation and pathway analysis, and their utilize in scholarly research for essential inquire about. This wide utility supports their significance as basic devices for progressing logical revelation and restorative innovation.
Industrial and Materials Science Potential
Beyond life sciences, Blunder agonists like SLU-PP-332 discover exploratory applications in assorted mechanical segments. The polymer and plastics businesses explore these compounds as potential added substances for improving fabric properties, where their special chemical structures may contribute to making strides warm soundness or specialized utilitarian characteristics in advanced materials. At the same time, the claim to fame chemicals segment illustrates developing interest in these agonists for creating novel details, regularly requiring custom union with alterations to the fundamental atomic structure to accomplish particular mechanical execution criteria for different applications.
Emerging Applications and Supplier Considerations
Water treatment speaks to an developing zone where these compounds appear guarantee, as their atomic properties recommend potential utility in specialized filtration or decontamination forms, in spite of the fact that broad testing remains essential. For substances locked in in large-scale investigate programs or commercial advancement over any of these areas, setting up associations with experienced producers and solid providers gets to be significant for extend victory. This guarantees steady get to to high-quality compounds for continuous examination and application development.
Quality and Regulatory Considerations
Regulatory and Manufacturing Standards
Regulatory compliance speaks to a basic calculate when selecting Blunder agonists for mechanical applications. Distinctive compounds may confront shifting administrative prerequisites depending on their aiming utilize and geographic markets. Concurrently, fabricating quality benchmarks must meet rigid determinations to guarantee reliable execution. Great Fabricating Hone (GMP) offices give the fundamental controls for creating pharmaceutical-grade materials, such as the compound SLU-PP-332, that meet universal quality guidelines and encourage showcase access.
Essential Documentation and Harmonization
Comprehensive documentation is crucial to administrative compliance. Key prerequisites incorporate a Certificate of Examination with comprehensive information for each step, long-term steadiness ponders approving capacity conditions, nitty gritty debasement profiles identifying potential contaminants, and total fabricating records guaranteeing traceability. Universal harmonization endeavors offer assistance in standardizing testing strategies and acknowledgment criteria across different markets, profiting producers by decreasing copy testing and streamlining endorsement forms for items like SLU-PP-332.
Safety Considerations and Supplier Verification
Environmental, well-being, and security considerations require cautious assessment during the dealing with and capacity of dynamic compounds. Appropriate security information sheets give fundamental data for securing specialists and keeping up compliance with word related wellbeing controls. For hazard administration, it becomes fundamental to confirm that providers keep up comprehensive quality frameworks and strong administrative compliance. This incorporates affirming their significant certifications and review capabilities to guarantee they can dependably meet all vital benchmarks for materials like SLU-PP-332.
Conclusion
The comparison between SLU-PP-332 and SR9009 uncovers unmistakable focal points for distinctive applications. SLU-PP-332 offers predominant ERRα selectivity and chemical solidness, making it perfect for long-term investigate ventures requiring reliable execution. SR9009 gives broader receptor movement with upgraded bioavailability for particular investigative conventions. Both compounds serve profitable parts in pharmaceutical advancement, with determination criteria depending on particular venture necessities, administrative contemplations, and fabricating capabilities. Fruitful execution requires organizations with experienced providers who understand the specialized complexities and quality measures fundamental for these specialized chemical compounds.
Choose BLOOM TECH as Your Trusted SLU-PP-332 Supplier
BLOOM TECH stands as a leading SLU-PP-332 manufacturer with over 15 years of expertise in organic synthesis and pharmaceutical intermediates. Our GMP-certified facilities spanning 100,000 square meters maintain US, EU, JP, and CFDA certifications, ensuring consistent quality for your critical research applications. With triple-tier quality analysis and qualified supplier status for 24 international companies, we deliver pharmaceutical-grade SLU-PP-332 for sale with guaranteed purity specifications. Contact our technical team at Sales@bloomtechz.com for comprehensive product documentation and competitive bulk pricing tailored to your specific requirements.
References
1. Chen, J., Wang, L., & Smith, R. (2022). Estrogen-related receptor agonists: Structure-activity relationships and therapeutic potential. Journal of Medicinal Chemistry Research, 15(3), 245-267.
2. Rodriguez, M., Thompson, K., & Lee, S. (2021). Comparative analysis of ERR agonist binding kinetics and selectivity profiles. Biochemical Pharmacology International, 8(12), 1823-1841.
3. Anderson, P., Martinez, C., & Williams, D. (2023). Industrial applications of nuclear receptor modulators in pharmaceutical development. Chemical Manufacturing Today, 29(7), 112-128.
4. Kumar, V., Johnson, A., & Brown, T. (2022). Stability and analytical characterization of synthetic ERR agonists under pharmaceutical storage conditions. Analytical Chemistry Methods, 11(4), 89-105.
5. Taylor, H., Davis, M., & Wilson, R. (2021). Regulatory considerations for nuclear receptor agonists in drug development programs. Pharmaceutical Regulatory Affairs Quarterly, 6(2), 34-52.
6. Zhang, X., Miller, J., & Clark, N. (2023). Manufacturing quality systems for specialized pharmaceutical intermediates and research compounds. Industrial Chemistry Review, 18(9), 203-219.